pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Novo Nordisk Inc · news · pharmadog
← back to Novo Nordisk Inc
News mentioning Novo Nordisk Inc
167
stories
23d
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
fiercebiotech
23d
Biotechs bring big launches and pharma rivalries into Q2 earnings period
biospace
24d
FDA offers updated guidance for generics of weight loss blockbusters
endpoints
24d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
24d
Altimmune’s next-gen GLP-1 curbs heavy drinking in ‘unequivocal’ ph. 2 alcohol use disorder win
fiercebiotech
25d
‘This could be a large market’: Novo Holdings-backed Claris secures $118M for corneal disease drug
fiercebiotech
25d
Denmark’s foundation‑fueled biotech boom redraws the Nordic map
biospace
28d
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
28d
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
biopharma dive
28d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
29d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
29d
STAT+: European regulators take steps to bolster clinical trial transparency
stat
29d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
29d
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
29d
STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
stat
29d
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
stat
29d
Biopharma layoffs must double in H2 for 2026 to match 2025 cuts
biospace
Jul 22, 26
STAT+: Pharmalittle: We’re reading about Trump’s plan for tariffs on generics, a Merck and Gilead HIV pill, and more
stat
Jul 21, 26
Novo sues Lilly over 'deceptive' ads comparing GLP-1 drug doses
endpoints
Jul 21, 26
Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesity
biospace
Jul 21, 26
Agios scraps sickle cell drug
biopharma dive
Jul 21, 26
Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs
biopharma dive
Jul 21, 26
Agios axes next-gen sickle cell candidate after it fails to best Novo’s asset
biospace
Jul 21, 26
Is there an exodus underway at Epic?
stat
Jul 21, 26
STAT+: Anthropic deepens work with rare disease drugs
stat
Jul 21, 26
STAT+: Pharmalittle: We’re reading about Novo suing Lilly over ‘deceptive’ ads, a fugitive’s secret life in biotech, and more
stat
Jul 21, 26
STAT+: Nabla’s new CEO on plan to gain market share in a competitive AI scribe environment
stat
Jul 21, 26
STAT+: Novo Nordisk sues Eli Lilly over GLP-1 drug ads it calls ‘deceptive’
stat
Jul 21, 26
Agios says adios to sickle cell program over lackluster phase 2 data
fiercebiotech
Jul 20, 26
Pain drugmaker Latigo outlines plans to go public
biopharma dive
← prev
page 3 of 6
next →
